Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial

References

• European Centre for Disease Prevention and Control. Disease data from ECDC surveillance Atlas for meningococcal disease. European Centre for Disease Prevention and Control. 2018. https://www.ecdc.europa.eu/en/meningococcal-disease/surveillance-and-disease-data/atlas
   Google Scholar
• Parikh SR, Campbell H, Bettinger JA, Harrison LH, Marshall HS, Martinon-Torres F, Safadi MA, Shao Z, Zhu B, von Gottberg A, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483–8. doi:10.1016/j.jinf.2020.05.079.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Factsheet about meningococcal disease. 2019. https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet
   Google Scholar
• Aparecido Nunes A, De Jesus Lopes De Abreu A, Cintra O, Actc M, Barbosa Coelho E, Nogueira Castro De Barros E. Meningococcal disease epidemiology in Brazil (2005-2018) and impact of MenC vaccination. Vaccine. 2021;39:605–16. doi:10.1016/j.vaccine.2020.11.067.
   PubMed Web of Science ®Google Scholar
• Australian Government-Department of Health. Invasive meningococcal disease National Surveillance Report-1 January to 30 June 2019. Invasive Meningococcal Disease National Surveillance Report: Australian Government-Department of Health; 2019. https://www1.health.gov.au/internet/main/publishing.nsf/Content/5FEABC4B495BDEC1CA25807D001327FA/$File/IMD-surveil-report-Jan-June-2019.pdf
   Google Scholar
• Knol MJ, Hahne SJM, Lucidarme J, Campbell H, de Melker HE, Gray SJ, Borrow R, Ladhani SN, Ramsay ME, van der Ende A, et al. Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study. Lancet Public Health. 2017;2:e473–e82. doi:10.1016/S2468-2667(17)30157-3.
   PubMed Web of Science ®Google Scholar
• Poellabauer EM, Pavlova BG, Fritsch S, Singer J, Neubauer C, Doralt J, Valenta-Singer B, Ehrlich HJ. Single priming dose of meningococcal group C conjugate vaccine (NeisVac-C®) in infants. Vaccine. 2013;31:3611–16. doi:10.1016/j.vaccine.2013.04.070.
   PubMed Web of Science ®Google Scholar
• Findlow H, Campbell H, Lucidarme J, Andrews N, Linley E, Ladhani S, Borrow R. Serogroup C Neisseria meningitidis disease epidemiology, seroprevalence, vaccine effectiveness and waning immunity, England, 1998/99 to 2015/16. Euro Surveill. 2019;24. doi:10.2807/1560-7917.ES.2019.24.1.1700818.
   PubMedGoogle Scholar
• Bijlsma MW, Brouwer MC, Spanjaard L, van de Beek D, van der Ende A. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination. Clin Infect Dis. 2014;59:1216–21. doi:10.1093/cid/ciu601.
   PubMed Web of Science ®Google Scholar
• Knol MJ, Ruijs WL, Antonise-Kamp L, de Melker HE, van der Ende A. Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018. Eurosurveillance. 2018;23:18–00158. doi:10.2807/1560-7917.ES.2018.23.16.18-00158.
   Web of Science ®Google Scholar
• Booy R, Gentile A, Nissen M, Whelan J, Abitbol V. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum Vaccin Immunother. 2019;15:470–80. doi:10.1080/21645515.2018.1532248.
   PubMed Web of Science ®Google Scholar
• Presa J, Findlow J, Vojicic J, Williams S, Serra L. Epidemiologic trends, global shifts in meningococcal vaccination guidelines, and data supporting the use of MenACWY-TT vaccine: a review. Infect Dis Ther. 2019;8:307–33. doi:10.1007/s40121-019-0254-1.
   PubMed Web of Science ®Google Scholar
• Kirstein J, Pina M, Pan J, Jordanov E, Dhingra MS. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study. Hum Vaccin Immunother. 2020;16:1299–305. doi:10.1080/21645515.2020.1733868.
   PubMed Web of Science ®Google Scholar
• Esteves-Jaramillo A, Koehler T, Jeanfreau R, Neveu D, Jordanov E, Singh Dhingra M. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in >/=56-year-olds: a Phase III randomized study. Vaccine. 2020;38:4405–11. doi:10.1016/j.vaccine.2020.04.067.
   PubMed Web of Science ®Google Scholar
• Chang LJ, Hedrick J, Christensen S, Pan J, Jordanov E, Dhingra MS. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine. 2020;38:3560–69. doi:10.1016/j.vaccine.2020.03.017.
   PubMed Web of Science ®Google Scholar
• Anez G, Hedrick J, Simon MW, Christensen S, Jeanfreau R, Yau E, Pan J, Jordanov E, Dhingra MS. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study. Hum Vaccin Immunother. 2020;16:1292–98. doi:10.1080/21645515.2020.1733867.
   PubMed Web of Science ®Google Scholar
• Baccarini CI, Simon MW, Brandon D, Christensen S, Jordanov E, Dhingra MS. Safety and Immunogenicity of a quadrivalent meningococcal conjugate vaccine in healthy meningococcal-naive children 2-9 years of age: a Phase III, randomized study. Pediatr Infect Dis J. 2020;39:955–60. doi:10.1097/INF.0000000000002832.
   PubMed Web of Science ®Google Scholar
• Dhingra MS, Peterson J, Hedrick J, Pan J, Neveu D, Jordanov E. Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study. Vaccine. 2020;38:5194–201. doi:10.1016/j.vaccine.2020.06.013.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Borrow R, Forsten A, Findlow H, Dhingra MS, Jordanov E. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study. Hum Vaccin Immunother. 2020;16:1306–12. doi:10.1080/21645515.2020.1733869.
   PubMed Web of Science ®Google Scholar
• van der Vliet D, Vesikari T, Sandner B, Martinon-Torres F, Muzsay G, Forsten A, van der Vliet D, Adelt T, Diaz Gonzalez C, Simko R, et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study. Epidemiol Infect. 2021;149:e50. doi:10.1017/S0950268821000261.
   PubMed Web of Science ®Google Scholar
• Dhingra MS, Namazova-Baranova L, Arredondo-Garcia JL, Kim KH, Limkittikul K, Jantarabenjakul W, Perminova O, Kobashi IAR, Bae C-W, Ojeda J, et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study. Epidemiol Infect. 2021;149:e90. doi:10.1017/S0950268821000698.
   PubMed Web of Science ®Google Scholar
• Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, et al.; The Multilaboratory Study Group. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol. 1997;4:156–67. doi:10.1128/cdli.4.2.156-167.1997.
   PubMedGoogle Scholar
• Martinón-Torres F, Bertrand-Gerentes I, Oster P. A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT. Expert Rev Vaccines. 2021;20:1123–46. doi:10.1080/14760584.2021.1964962.
   PubMed Web of Science ®Google Scholar
• Serra L, Knuf M, Martinon-Torres F, Yi K, Findlow J. Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines. Hum Vaccin Immunother. 2021;17:2205–15. doi:10.1080/21645515.2020.1855952.
   PubMed Web of Science ®Google Scholar
• Findlow J, Knuf M. Immunogenicity and safety of meningococcal group A, C, W and Y tetanus toxoid conjugate vaccine: review of clinical and real-world evidence. Future Microbiol. 2019;14:563–80. doi:10.2217/fmb-2018-0343.
   PubMed Web of Science ®Google Scholar
• Campbell H, Edelstein M, Andrews N, Borrow R, Ramsay M, Ladhani S. Emergency meningococcal ACWY vaccination program for teenagers to control group W meningococcal disease, England, 2015-2016. Emerg Infect Dis. 2017;23:1184–87. doi:10.3201/eid2307.170236.
   PubMed Web of Science ®Google Scholar
• Piazza FM, Virta M, Paassilta M, Ukkonen B, Ahonen A, Esteves-Jaramillo A, Forsten A, Seppa I, Ding J, Neveu D, et al. Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: a Phase III, open-label, multi-center study. Hum Vaccin Immunother. 2021;1–10. doi:10.1080/21645515.2021.1902701
   PubMed Web of Science ®Google Scholar